Analysts Offer Insights on Healthcare Companies: Cigna (CI), Jazz Pharmaceuticals (JAZZ) and Lifestance Health Group (LFST)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cigna (CI), Jazz Pharmaceuticals (JAZZ) and Lifestance Health Group (LFST) with bullish sentiments.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Cigna (CI)
In a report released today, Kevin Fischbeck from Bank of America Securities maintained a Buy rating on Cigna, with a price target of $378.00. The company’s shares closed last Tuesday at $295.00.
According to TipRanks.com, Fischbeck is a 2-star analyst with an average return of
Cigna has an analyst consensus of Strong Buy, with a price target consensus of $341.94, a 17.6% upside from current levels. In a report issued on May 27, Bernstein also maintained a Buy rating on the stock with a $371.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Jazz Pharmaceuticals (JAZZ)
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Jazz Pharmaceuticals today and set a price target of $307.00. The company’s shares closed last Tuesday at $229.19.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $262.29 average price target, a 10.7% upside from current levels. In a report released yesterday, Truist Financial also initiated coverage with a Buy rating on the stock with a $256.00 price target.
Lifestance Health Group (LFST)
In a report released today, Ryan Daniels from William Blair maintained a Buy rating on Lifestance Health Group. The company’s shares closed last Tuesday at $7.66.
According to TipRanks.com, Daniels is a 2-star analyst with an average return of
Lifestance Health Group has an analyst consensus of Strong Buy, with a price target consensus of $10.50, representing a 41.5% upside. In a report issued on June 5, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $8.50 price target.
Read More on CI:
